Anticancer effects of Coumarin Sulfonamides

Subjects: Biochemical Research Methods

Contributor: Mariusz Mojzych

Coumarin is an important six-membered aromatic heterocyclic pharmacophore, widely distributed in natural products and synthetic molecules. The versatile and unique features of coumarin nucleus, in combination with privileged sulfonamide moiety, have enhanced the broad spectrum of biological activities. The research and development of coumarin, sulfonamide-based pharmacology, and medicinal chemistry have become active topics, and attracted the attention of medicinal chemists, pharmacists, and synthetic chemists. Coumarin sulfonamide compounds and analogs as clinical drugs have been used to cure various diseases with high therapeutic potency, which have shown their enormous development value. The diversified and wide array of biological activities such as anticancer, antibacterial, anti-fungal, antioxidant and anti-viral, etc. were displayed by diversified coumarin sulfonamides.

Keywords: coumarin sulfonamide ; anticancer agents

1. Introduction

Ever since the first time that coumarin **1** was isolated from natural source tonka bean (*Dipteryx odorata*), commonly known as cumaru, in 1820 by Vogel [1][2]. Coumarin is an old, important, and diversified oxygen containing six membered heterocyclic classes of 1,2 benzopyrones, which naturally occur in plants and many other species, such as fungi (*Armillariella tabescens, Fomitopsis officinalis*) and bacteria (*Streptomyces niveus, Escherichia coli*) [3][4]. More than 1300 coumarins are present in plants, which play vital role in physiology and overall functioning of plants [1]. The general structure of coumarin **1** is given below (**Figure 1**). In the mid-nineteenth century, the research and development of coumarin-based compounds and hybrid structures began via the famous Perkin condensation reaction between acetic anhydride and salicylaldehyde. The different synthetic classical techniques, such as Knoevenagel, Perkin and Pechmann reactions, are applied to achieve simple coumarins [5][6][7]. The rapid developments in the synthetic chemistry of coumarins have been made, due to their wide therapeutic potential as medicinal drugs. The coumarin scaffolds displayed an array of biological activities, such as coumarin chalcone derivatives, coumarin aryl sulfonamides, and coumarin hydrazine–hydrazone hybrids, etc., which were screened to investigate their anticancer activities [8][9][10][11][12]. Coumarin scaffolds are extensively studied for their antioxidant [13][14][15][16], antibacterial [17][18][19][20], anti-fungal [21][22][23], anti-inflammatory [24][25], anti-diabetic [26], vasorelaxant [27], analgesic [28], anti-HIV [29], antimicrobial [30], anti-coagulation [31], and anti-pyretic [32] activities, etc.



Figure 1. Structure of coumarin **1**.

2. Coumarin Sulfonamides as Anti-Cancer Agents and Carbonic Anhydrase Inhibitors

Cancer is one of the most lethal, notable complex and serious threats to human health, and has attracted attention worldwide. All over the world, about 7.6 million people die due to cancer every year, and around 13 million people will likely die before 2030. In 2020, globally, almost 10 million people died due to cancer [33][34]. Extensive research and development work have been conducted in the field of oncology to develop anticancer therapeutic agents, and large breakthroughs and great strides have been made over past 60 years [35]. Coumarin sulfonamide derivatives and analogs have therapeutic potential against different types of cancer cell lines and CAs (carbonic anhydrases). CAs are also known as carbonate dehydratases [36]. CAs are metalloenzymes which are present in all life forms, and are essential for equilibria between different simple but significant reaction species, such as carbon dioxide, proton, and bicarbonate [37][38][39][40][41]. In 1933, 88 years ago, these enzymes were discovered, and are still an extraordinary example of convergent evolution, and extensively studied and investigated for biomedical inhibitory activities. CAs were found in bacteria, archaea and eukarya; genetically, at least eight (α-, β-, γ-, δ-, ζ-, η-, θ- and ι-CAs) distinct families [37][38][39][40][41][42]. The α-CAs family is present in vertebrates, and the bacteria, algae, and cytoplasm of green plants, while β-CAs are found in bacteria, the chloroplasts of monodicotyledons and dicotyledons, and algae. The γ-CAs are mainly present in archaea and some bacteria, the δ-, ζ- and θ-CAs are present in some marine diatoms, and the η-CAs are present in protozoa. The ι-CAs were discovered in marine phytoplankton, as well as in some bacteria [42][43][44][45][46][47][48][49][50][51][52]. There are five membrane-bound isozymes: CA-IV, CA-IX, CA-XII, CA-XIV, and CA-XV), five cytosolic forms CA-I, CA-II, CA-III, CA-VII, and CA-XIII, a secreted CA isozyme CA-VI, and two mitochondrial forms, CA-VA and CA-VB [53][54][55][56][57]. CAs inhibition mechanism with coumarins was unraveled with kinetic and X-ray crystallographic techniques. The first natural product, coumarin, was bound to human isoform hCA-II, but the formation of the enzyme inhibitor complex is not a rapid process, it takes 6 h for incubation period, while other classes take just 15 min for the incubation period [58][59][60][61][62][63]. The coumarin sulfonamides' anticancer and CAs inhibition activities are discussed below in more detail.

2.1. Benzenesulfonamide-Based Coumarins as Carbonic Anhydrases II and IX Inhibitors

Wang and coworkers designed a solvent-free green methodology to synthesize substituted coumarin containing sulfonamides derivatives, and screened for carbonic anhydrase inhibitory activities. In this synthetic strategy, Meldrum's acid was reacted with various substituted phenol **5** to achieve substituted malonic acid-based mono phenol esters **6** in (91–94%) yield, which further cyclized with Eaton's reagent under mild conditions to yield 4-hydroxycoumarin **7** in (79–91%) yield. In the next step, substituted 3-formyl-4-chlorocoumarin **8** (59–73%) was obtained by Vilsmeiere Haack reactions in dimethylformamide (DMF) and phosphoryl chloride. Derivative **8** was treated with substituted sulfonamides in ethanol at room temperature (rt) to 50 °C, leading to the formation of final coumarin sulfonamide derivative **9** in (45–79%) yield (Scheme 1) [64].



Scheme 1. Synthesis of coumarin containing sulfonamide derivative **9**.

The benzenesulfonamide coumarins' eighteen derivatives were afforded and screened for their in vitro anticancer activity against mouse melanoma cells (B16–F10) and breast carcinoma cell lines (MCF-7), and two human carbonic anhydrase

against hCAs II (cytosolic off target isoform) and hCAs IX (trans-membrane tumor-associated isoform). The IC_{50} calculations were done by using Origin 8.6 software using an inhibitory model with the sum of squares of the residuals minimized. The most active derivative was substituted dimethyl pyrimidine-based coumarin benzene sulfonamide **9a** (**Figure 2**), which displayed the highest and remarkable significant anticancer potential against MCF-7 cell lines with IC_{50} 0.0088 µM when compared with the reference drugs doxorubicin IC_{50} 0.072 µM and semaxanib IC_{50} 0.012 µM. Both the virtual screening and anticancer activity results for MCF-7 showed that the over-expressed CA might be the most active therapeutic candidate that coumarin sulfonamides interacted with. The substituted pyrimidine-based coumarin benzene sulfonamide **9b** (**Figure 2**) and di-*tert*-butyl substituted coumarin benzenesulfonamide containing pyrimidine **9c** (**Figure 2**) displayed strong inhibition against hCAs II and hCAs IX isoforms with IC_{50} values of 0.063 µM and 0.124 µM (**Table 1**) respectively, when compared with standard drugs acetazolamide (AAZ) and sulfanilamide (SA). The SAR studies investigated that the introduction of thiazole and methyl pyrimidine substitutions in the benzenesulfonyl ring of the coumarin enhanced the anticancer and carbonic anhydrase inhibition activities of the below-mentioned coumarin derivatives [64].



Figure 2. Structure of the most active anticancer and CA inhibitors coumarin sulfonamides **9a**–**9c**.

Table 1. Anticancer data of compound **9a** and CAs inhibition data of compounds **9b** and **9c**.

Compound	MCF-7 µM	Compounds	hCAs II µM	hCAs IX µM
9a	**0.0088**	**9b**	**-**	**0.124**
Doxorubicin	**0.065**	**9c**	**0.063**	**-**
Semaxanib	**0.0031**	**AAZ**	**0.016**	**0.028**
-	**-**	**SA**	**0.26**	**0.29**

2.2. Thiazole-Sulfonamide Coumarin Hybrids as hCA I and hCA II Inhibitors

Kurt and colleagues developed a solvent-free approach to achieve the unsubstituted thiazole-based coumarin sulfonamides **17** by the reaction of 2-hydroxybenzaldehyde **10**, L-proline and ethyl 3-oxobutanoate **11**, by heating for 0.5 h at a temperature of 80–90 °C to obtain 3-acetylcoumarin **12** in 92% yield, which further refluxed for 15 min in chloroform and bromine solutions to obtain 3-(bromoacetyl) coumarin **13** in 98% yield. Refluxing compound **13** with thiourea **14** in ethanol for 1 h gives 2-amino coumarin thiazolyl derivatives **15** (90% yield) that were further treated with benzenesulfonyl chloride **16** derivatives at 60 °C in pyridine, which led to the synthesis of thiazole-based coumarin sulfonamides **17** in 68–82% yield (Scheme 2) [65].



Scheme 2. Solvent-free synthesis of coumarin sulfonamide derivatives **17**.

The thiazole ring of acetazolamide was combined with coumarin moiety to afford biologically active, substituted benzenesulfonamide-based coumaryl thiazole hybrids, and was screened for its anticancer activity against hCA I and hCA II (human carbonic anhydrase isoforms). Among all these compounds, the scaffold coumarin-thiazole-based naphthalene-2-sulpho-namide **17a** (**Figure 3**) displayed the strongest inhibition against hCA I and hCA II with the IC_{50} values 5.63 µM and 8.48 µM (**Table 2**), respectively. The SAR showed that bulky substituents such as s *tert*-butyl, naphthalene and iodine increase inhibitory activity, so compound **17a** showed the most potent inhibitory activity due to the steric effect of bulky group substitution, such as naphthalene on sulfonyl group against hCA I and hCA II [65].



Figure 3. Structures of the most active antioxidant and CA inhibitors coumarin sulfonamides **17a**.

Table 2. CAs inhibition data and antioxidant data of compounds **17a**–**17b**.

Compound	hCA I IC_{50} (µM)	hCA II IC_{50} (µM)
17a	**5.63**	**8.48**

2.3. Sulfonyl Ureido Coumarins Hybrids as Carbonic Anhydrase Inhibitors

Bozdag and collogues described a single step reaction to afford substituted sulfonyl ureido coumarins **20** in 53–88% yield by the treatment of coumarin **18** and sulfonyl ureido isocyanates **19** in acetonitrile (ACN) or dry acetone (Scheme 3) [66].



Scheme 3. Synthesis of substituted sulfonyl ureido coumarins **20**.

The ary lsulfonylureido coumarin derivatives were evaluated for their inhibitory activity against hCA I and II (carbonic anhydrase cytosolic inhibitor) and hCA IX and XII (tumor-associated isoforms). The 4-chloro-substituted coumarin benzenesulfonamide **20a** (**Figure 4**) exhibited the highest inhibitory activity with a K_I value 20.2 nM against hCA IX and 6.0 nM against hCA XII (**Table 3**). Acetazolamide (AAZ) was used as a standard reference drug with K_I = 25.0 nM and K_I = 5.7 nM (**Table 3**) against hCA IX and hCA XII, respectively. The SAR showed that analogue **20a** was the most potent due to the presence of electron withdrawing Cl atom in the benzene ring of the sulfonyl ureido group [66].



Figure 4. Structures of the most active coumarin sulfonamide CA inhibitor **20a**.

Table 3. CAs inhibition data compound **20a**.

Compound	hCA IX K_I (nM)	hCA XII K_I (nM)
20a	**20.2**	**6.0**
AAZ	**25.0**	**5.7**

2.4. Benzene Sulfonamido-Coumarinyl Hydrazones Hybrids as CA Inhibitors

Chandak et al., in 2016, synthesized sulfonamide bearing coumarin derivatives by a Hantzsch thiazole synthetic approach as shown in Scheme 4. In this synthetic strategy, the thiazoyl hydrazine methylidene pyrazole **31** derivatives were achieved from 4-hydrazinobenzenesulfonamide hydrochloride, further converted into pyrazole-based carbaldehyde bearing thiosemicarbazones, and finally reacted to substituted bromoacetyl-based coumarins **30** by condensation reaction. In the second step, different 6-substituted 3-bromoacetylcoumarins **30** and 4-thioureido-benzenesulfonamide achieved 2-amino-substituted-coumarinylthiazoles **32** by condensation reaction. In the next step, heterocyclic series **33** containing three IBTs prepared by treatment of 2-aminobenzothiazole-6-sulfonamide that first obtained from sulfanilamide and 6-substituted-3-bromoacetylcoumarins. On the other hand, the derivatives of series 4, different 3-acetylcoumarins **29** and 4-hydrazinobenzenesulfonamide hydrochloride **34** by refluxing together in aqueous ethanol with anhydrous sodium acetate, give benzenesulfonamido-coumarinyl hydrazones, **35** (Scheme 4) [67].



Scheme 4. Synthesis of sulfonamide bearing coumarin derivatives **31**–**35**.

The following sulfonamide-bearing coumarin scaffold consisted of twenty-four compounds evaluated for the inhibition of hCA I, II, IX and XII (human carbonic anhydrase isoforms). Among all of these, the **32a** compound (**Figure 5**) exhibited strong potent inhibitory activity with a K_I value 2.28 nM (**Table 4**) against hCA IX, as compared to standard compound AZA with a K_I range 25.0 nM. Moreover, analogues **32a** and **32b** were most potent with K_I values 0.54 nM against hCA XII when compared to AZA with a K_I value 5.7 nM. The hybrid structure 4-{2-[1-(2-oxo-2*H*-chromen-3-yl)ethylidene]hydrazino} benzenesulfonamide **35a** revealed the highest activity K_I = 13.23 nM for hCA II in comparison with reference drug AZA with K_I value 12.1 nM. The compound 4-{2-[1-(6-bromo-2-oxo-2*H*-chromen-3-yl)ethylidene]hydrazino}benzenesulfonamide **35b** (**Figure 5**) screened potent inhibitory activity with a K_I value 21.95 nM against hCA I, as compared to standard compound AZA (acetazolamide) with a K_I range 250.0 nM (**Table 4**). The SAR showed that the introduction of bromo and unsubstituted H-atom on coumarin increase the carbonic anhydrase inhibitory activity of derivatives **35a** and **35b** (**Figure 5**), while the presence of electron-withdrawing Cl-atom and unsubstituted H-atom on coumarin enhances the inhibitory activity of compounds **32a** and **32b** [67].



Figure 5. Structures of the most active coumarin sulfonamide CA inhibitors **32a**–**32b** and **35a**–**35b**.

Table 4. Coumarin sulfonamide as CA inhibitors **32a**–**32b** and **35a**–**35b**.

Compound Number	hCA I K_I (nM)	hCA II K_I (nM)	hCA IX K_I (nM)	hCA XII K_I (nM)
32a	263.49	21.20	2.28	0.54
32b	349.63	17.46	2.54	0.54
35a	220.13	13.23	58.61	4.4
35b	21.95	1751.72	23.59	0.62
AZA	250.0	12.1	25.0	5.7

References

1. De Souza, L.G.; Rennã, M.N.; Figueroa-Villar, J.D. Coumarins as cholinesterase inhibitors. A review. Chem. Biol. Interact. 2016, 254, 11–23.
2. Peng, X.M.; Damu, L.V.; Zhou, C.H. Current developments of coumarin compounds in medicinal chemistry. Curr. Pharm. Des. 2013, 19, 3884–3930.
3. Kostova, I. Synthetic and natural coumarins as antioxidants. Mini Rev. Med. Chem. 2006, 6, 365–374.
4. Pereira, M.T.; Franco, P.D.; Vitorio, F.; Kümmerle, E.A. Coumarin compounds in medicinal chemistry: Some important examples from the last years. Curr. Top. Med. Chem. 2018, 18, 124–148.
5. Murray, R.D.H. Coumarins. Nat. Prod. Rep. 1995, 12, 477–505.
6. Pereira, T.M.; Vitório, F.; Amaral, R.C.; Zanoni, K.P.S.; Iha, N.Y.M.; Kümmerle, A.E. Microwave-assisted synthesis and photophysical studies of novel fluorescent N-acylhydrazone and semicarbazone-7-OH-coumarin dyes. New J. Chem. 2016, 40, 8846–8854.
7. Symeonidis, T.; Chamilos, M.; Litina, D.J.H.; Kallitsakis, M.; Litinas, K.E. Synthesis of hydroxycoumarins and hydroxybenzo- or coumarins as lipid peroxidation inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1139–1142.
8. Sashidhara, K.V.; Kumar, A.; Kumar, J.M.; Sinha, S.S. Synthesis and in vitro evaluation of novel coumarinechalcone hybrids as potential anticancer agents. Bioorg. Med. Chem. Lett. 2010, 20, 7205–7721.
9. Reddy, N.S.; Mallireddigari, M.R.; Cosenza, S.; Gumireddy, K.; Bell, S.C.; Reddy, E.P.; Reddy, M.R. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg. Med. Chem. Lett. 2004, 14, 4093–4097.
10. Nasr, S.T.; Bondock, M. Youns, Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. Eur. J. Med. Chem. 2014, 76, 539–548.
11. Thakur, A.; Singla, R.; Jaitak, V. Coumarins as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Eur. J. Med. Chem. 2015, 101, 476–495.
12. Devji, T.; Reddy, C.; Woo, C.; Awale, S.; Kadota, S.; Carrico-Moniz, D. Pancreatic anticancer activity of a novel geranyl geranylatedcoumarin derivative. Bioorg. Med. Chem. Lett. 2011, 21, 5770–5773.
13. Alshibl, H.M.; Al-Abdullah, E.S.; Haiba, M.E.; Alkahtani, H.M.; Awad, G.E.A.; Mahmoud, A.H.; Ibrahim, B.M.M.; Bari, A.; Villinger, A. Synthesis and Evaluation of New Coumarin Derivatives as Antioxidant, Antimicrobial, and Anti-Inflammatory Agents. Molecules 2020, 25, 3251.
14. Melagraki, G.; Afantitis, A.; Igglessi-Markopoulou, O.; Detsi, A.; Koufaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D.J. Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur. J. Med. Chem. 2009, 44, 3020–3026.
15. Fylaktakidou, K.C.; Hadjipavlou-Litina, D.J.; Litinas, K.E.; Nicolaides, D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr. Pharm. Des. 2004, 10, 3813–3833.
16. Kontogiorgis, C.; Hadjipavlou-Litina, D. Biological evaluation of several coumarins derivatives designed as possible anti-inflammatory/antioxidant agents. J. Enzym. Inhib. Med. Chem. 2003, 18, 63–69.
17. Rehman, S.U.; Chohan, Z.H.; Gulnaz, F.; Supuran, C.T. In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J. Enzym. Inhib. Med. Chem. 2005, 20, 333–340.
18. Kalluraya, B.; Vishwanatha, P.; Isloor, A.M.; Rai, G.; Kotian, M. Synthesis and biological activity of 6-substituted-3- coumarins. Boll. Chim. Farm. 2000, 139, 263–266.
19. Musiciki, B.; Periers, A.M.; Laurin, P.; Ferroud, D.; Benedetti, Y.; Lachaud, S.; Chatreaux, F.; Haesslein, J.L.; LLtis, A.; Pierre, C.; et al. Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkylnoviose: Biological activity of

RU79115. Bioorg. Med. Chem. Lett. 2000, 10, 1695.

20. De Souza, S.M.; Monache, F.D.; Smânia, A. Antibacterial activity of coumarins. Z. Nat. C 2005, 60, 693–700.
21. Guerra, F.Q.S.; de Araújo, R.S.A.; de Sousa, J.P.; de Pereira, F.O.; Mendonça-Junior, F.J.B.; Barbosa-Filho, J.M.; de Oliveira Lima, E. Evaluation of antifungal activity and mode of action of new coumarin derivative, 7-hydroxy-6-nitro-2h-1-benzopyran-2-one, against Aspergillus spp. Evid. Based Complement. Altern. Med. 2015, 2015, 925096.
22. Montagner, C.; de Souza, S.M.; Groposo, C.; DelleMonache, F.; Smânia, E.F.A.; Smânia, A., Jr. Antifungal activity of coumarins. Z. Nat. C J. Biosci. 2008, 63, 21–28.
23. Sardari, S.; Mori, Y.; Horita, K.; Micetich, R.G.; Nishibe, S.; Daneshtalab, M. Synthesis and antifungal activity of coumarins and angular furanocoumarins. Bioorg. Med. Chem. 1999, 7, 1933–1940.
24. Ghate, M.; Manohar, D.; Kulkarni, V.; Shobha, R.; Kattimani, S.Y. Synthesis of vanillin ethers from 4-(bromomethyl) coumarins as anti-inflammatory agents. Eur. J. Med. Chem. 2003, 38, 297–302.
25. Christos, A.K.; Dimitra, J.H. Synthesis and anti-inflammatory activity of coumarin derivatives. J. Med. Chem. 2005, 48, 6400–6408.
26. Li, H.; Yao, Y.; Li, L. Coumarins as potential antidiabetic agents. J. Pharm. Pharmacol. 2017, 69, 1253–1264.
27. Campos-Toimil, M.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 783–786.
28. Ghate, M.; Kusanur, R.A.; Kulkarni, M.V. Synthesis and in vivo analgesic and anti-inflammatory activity of some bi heterocyclic coumarin derivatives. Eur. J. Med. Chem. 2005, 40, 882–887.
29. Kostova, I.; Raleva, S.; Genova, P.; Argirova, R. Structure-activity relationships of synthetic coumarins as hiv-1 inhibitors. Bioinorg. Chem. Appl. 2006, 2006, 68274.
30. Ojala, T.; Remes, S.; Haansuu, P.; Vuorela, H.; Hiltunen, R.; Haatela, K.; Vuorela, P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. J. Ethnopharmacol. 2000, 73, 299–305.
31. Abdelhafez, M.O.; Amin, M.K.; Batran, Z.R.; Maher, J.T.; Nada, A.S.; Sethumadhavan, S. Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin derivatives. Bioorg. Med. Chem. 2010, 18, 3371–3378.
32. Ahmad, R.; Asad, M.; Siddiqui, N.Z.; Kumar, A. Evaluation of antipyretic and antinociceptive potential of new heterocyclic derivatives of 3-formyl-4-hydroxycoumarin in rats. J. Pharm. Appl. Sci. 2013, 3, 253–259.
33. Hassanpour, S.H.; Dehghani, M. Review of cancer from perspective of molecular. J. Cancer Res. Pract. 2017, 4, 127–129.
34. Arruebo, M.; Vilaboa, N.; Sáez-Gutierrez, B.; Lambea, J.; Tres, A.; Valladares, M.; González-Fernández, Á. Assessment of the evolution of cancer treatment therapies. Cancers 2011, 3, 3279–3330.
35. Grasso, C.S.; Wu, Y.M.; Robinson, D.R.; Cao, X.; Dhanasekaran, S.M.; Khan, A.P.; Quist, M.J.; Jing, X.J.; Lonigro, R.J.; Brenner, J.C.; et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487, 239–243.
36. Irfan, A.; Rubab, L.; Rehman, U.M.; Anjum, R.; Ullah, S.; Marjana, M.; Qadeer, S.; Sana, S. Coumarin sulfonamide derivatives: An emerging class of therapeutic agents. Heterocycl. Commun. 2020, 26, 46–59.
37. Supuran, C.T. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzym. Inhib. Med. Chem. 2012, 27, 759–772.
38. Wagner, J.; Avvaru, S.B.; Robbins, H.A.; Scozzafava, A.; Supuran, T.C.; McKenna, R. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: Solution and crystallographic investigations. Bioorg. Med. Chem. 2010, 18, 4873–4878.
39. Supuran, C.T. Bacterial carbonic anhydrases as drug targets: Toward novel antibiotics. Front. Pharmacol. 2011, 2, 34.
40. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 2011, 10, 767–777.
41. Supuran, C.T. Carbonic anhydrase inhibitors: An editorial. Expert Opin. Ther. Pat. 2013, 23, 677–679.
42. Angeli, A.; Carta, F.; Supuran, C.T. Carbonic Anhydrases: Versatile and Useful Biocatalysts in Chemistry and Biochemistry. Catalysts 2020, 10, 1008.
43. Capasso, C.; Supuran, C.T. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: Can bacterial carbonic anhydrases shed new light on evolution of bacteria. J. Enzym. Inhib. Med. Chem. 2015, 30, 325–332.
44. Supuran, C.T.; Capasso, C. The η-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin. Ther. Targets 2015, 19, 551–563.

45. Del Prete, S.; Vullo, D.; De Luca, V.; Supuran, C.T.; Capasso, C. Biochemical characterization of the δ-carbonic anhydr ase from the marine diatom Thalassiosiraweissflogii, TweCA. J. Enzym. Inhib. Med. Chem. 2014, 29, 906–911.

46. Stefanucci, A.; Angeli, A.; Dimmito, M.P.; Luisi, G.; Del Prete, S.; Capasso, C.; Donald, W.A.; Mollica, A.; Supuran, C.T. Activation of β- and γ-carbonic anhydrases from pathogenic bacteria with tripeptides. J. Enzym. Inhib. Med. Chem. 201 8, 33, 945–950.

47. Angeli, A.; Del Prete, S.; Alasmary, F.A.S.; Alqahtani, L.S.; AlOthman, Z.; Donald, W.A.; Capasso, C.; Supuran, C.T. Th e first activation studies of the η-carbonic anhydrase from the malaria parasite Plasmodium falciparum with amines and amino acids. Bioorg. Chem. 2018, 80, 94–98.

48. Angeli, A.; Buonanno, M.; Donald, W.A.; Monti, S.M.; Supuran, C.T. The zinc—But not cadmium—Containing ζ-carboni c from the diatom Thalassiosiraweissflogii is potently activated by amines and amino acids. Bioorg. Chem. 2018, 80, 26 1–265.

49. Angeli, A.; Kuuslahti, M.; Parkkila, S.; Supuran, C.T. Activation studies with amines and amino acids of the α-carbonic a nhydrase from the pathogenic protozoan Trypanosoma cruzi. Bioorg. Med. Chem. 2018, 26, 4187–4190.

50. Angeli, A.; Del Prete, S.; Osman, S.M.; Alasmary, F.A.S.; AlOthman, Z.; Donald, W.A.; Capasso, C.; Supuran, C.T. Activ ation studies with amines and amino acids of the β-carbonic anhydrase encoded by the Rv3273 gene from the pathoge nic bacterium Mycobacterium tuberculosis. J. Enzym. Inhib. Med. Chem. 2018, 33, 364–369.

51. Angeli, A.; Del Prete, S.; Donald, W.A.; Capasso, C.; Supuran, C.T. The γ-carbonic anhydrase from the pathogenic bact erium Vibrio cholerae is potently activated by amines and amino acids. Bioorg. Chem. 2018, 77, 1–5.

52. Jensen, E.L.; Clement, R.; Kosta, A.; Maberly, S.C.; Gontero, B. A new widespread subclass of carbonic anhydrase in marine phytoplankton. ISME J. 2019, 13, 2094–2106.

53. Nishimori, I.; Minakuchi, T.; Onishi, S.; Vullo, D.; Cecchi, A.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitor s: Cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg. Med. Chem. 2 007, 15, 7229–7236.

54. Köhler, K.; Hillebrecht, A.; Schulze, W.J.; Innocenti, A.; Heine, A.; Supuran, C.T.; Klebe, G. Saccharin inhibits carbonica nhydrases: Possible explanation for its unpleasant metallic aftertaste. Angew. Chem. 2007, 46, 7697–7699.

55. Supuran, C.T.; Scozzafava, A.; Ilies, M.A.; Briganti, F. Carbonic anhydrase inhibitors. Synthesis of sulfonamides incorpo rating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo sele ctivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J. Enzym. Inhib. 2000, 15, 381–401.

56. Scozzafava, A.; Briganti, F.; Ilies, M.A.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis of membrane-imperme ant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus the cytosolic isoz ymes. J. Med. Chem. 2000, 43, 292–300.

57. De Simone, G.; Vitale, R.M.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Montero, J.L.; Winum, J.Y.; Supuran, C.T. Carbo nic anhydrase inhibitors:hypoxia-activatable sulfonamides incorporatingdisulfide bonds that target the tumor-associated isoform IX. J. Med. Chem. 2006, 49, 5544–5551.

58. Maresca, A.; Temperini, C.; Vu, H.; Pham, N.B.; Poulsen, S.A.; Scozzafava, A.; Quinn, R.J.; Supuran, C.T. Non-zinc me diated inhibition of carbonic anhydrases: Coumarins are a new class of suicide inhibitors. J. Am. Chem. Soc. 2009, 13 1, 3057–3062.

59. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C.T. Deciphering the mechanism of car bonic anhydrase inhibition with coumarins and thiocoumarins. J. Med. Chem. 2010, 53, 335–344.

60. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug. Disco v. 2008, 7, 168–181.

61. Supuran, C.T. Structure and function of carbonic anhydrases. Biochem. J. 2016, 473, 2023–2032.

62. Nocentini, A.; Supuran, C.T. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin. Drug Discov. 2019, 14, 1175–1197.

63. Supuran, C.T. Coumarin carbonic anhydrase inhibitors from natural sources. J. Enzym. Inhib. Med. Chem. 2020, 35, 14 62–1470.

64. Wang, Z.C.; Qin, Y.J.; Wang, P.F.; Yang, Y.A.; Wen, Q.; Zhang, X.; Qiu, H.Y.; Duan, Y.T.; Wang, Y.T.; Sang, Y.L.; et al. S ulfonamides containing coumarin moieties selectively and potently inhibit carbonic anhydrases II and IX: Design, synth esis, inhibitory activity and 3D-QSAR analysis. Eur. J. Med. Chem. 2013, 66, 1–11.

65. Kurt, B.Z.; Sonmez, F.; Bilen, C.; Ergun, A.; Gencer, N.; Arslan, O.; Kucukislamoglu, M. Synthesis, antioxidant and carb onic anhydrase I and II inhibitory activities of novel sulphonamide-substituted coumarylthiazole derivatives. J. Enzym. I

nhib. Med. Chem. 2016, 31, 78–89.

66. Bozdag, M.; Ferraroni, M.; Carta, F.; Vullo, D.; Lucarini, L.; Orlandini, E.; Rossello, A.; Nuti, E.; Scozzafava, A.; Masini, E.; et al. Structural insights on carbonic anhydrase inhibitory action, isoform selectivity, and potency of sulfonamides an d coumarins incorporating arylsulfonylureido groups. J. Med. Chem. 2014, 57, 9152–9167.

67. Chandak, N.; Ceruso, M.; Supuran, C.T.; Sharma, P.K. Novel sulfonamide bearing coumarin scaffolds as selective inhib itors of tumor associated carbonic anhydrase isoforms IX and XII. Bioorg. Med. Chem. 2016, 24, 2882–2886.